Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 22

1.

CYP17 inhibitors in prostate cancer: latest evidence and clinical potential.

Alex AB, Pal SK, Agarwal N.

Ther Adv Med Oncol. 2016 Jul;8(4):267-75. doi: 10.1177/1758834016642370. Epub 2016 Apr 19. Review.

2.

Promising Tools in Prostate Cancer Research: Selective Non-Steroidal Cytochrome P450 17A1 Inhibitors.

Bonomo S, Hansen CH, Petrunak EM, Scott EE, Styrishave B, Jørgensen FS, Olsen L.

Sci Rep. 2016 Jul 12;6:29468. doi: 10.1038/srep29468.

3.

CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma.

Noll EM, Eisen C, Stenzinger A, Espinet E, Muckenhuber A, Klein C, Vogel V, Klaus B, Nadler W, Rösli C, Lutz C, Kulke M, Engelhardt J, Zickgraf FM, Espinosa O, Schlesner M, Jiang X, Kopp-Schneider A, Neuhaus P, Bahra M, Sinn BV, Eils R, Giese NA, Hackert T, Strobel O, Werner J, Büchler MW, Weichert W, Trumpp A, Sprick MR.

Nat Med. 2016 Mar;22(3):278-87. doi: 10.1038/nm.4038. Epub 2016 Feb 8.

4.

Cancer chemoprevention: current state of the art.

Landis-Piwowar KR, Iyer NR.

Cancer Growth Metastasis. 2014 Jun 10;7:19-25. doi: 10.4137/CGM.S11288. eCollection 2014. Review.

5.
6.

Expression profile of CYP1A1 and CYP1B1 enzymes in colon and bladder tumors.

Androutsopoulos VP, Spyrou I, Ploumidis A, Papalampros AE, Kyriakakis M, Delakas D, Spandidos DA, Tsatsakis AM.

PLoS One. 2013 Dec 16;8(12):e82487. doi: 10.1371/journal.pone.0082487. eCollection 2013.

7.

Cytochrome P450 family 1 inhibitors and structure-activity relationships.

Liu J, Sridhar J, Foroozesh M.

Molecules. 2013 Nov 25;18(12):14470-95. doi: 10.3390/molecules181214470. Review.

8.

Smoke carcinogens cause bone loss through the aryl hydrocarbon receptor and induction of Cyp1 enzymes.

Iqbal J, Sun L, Cao J, Yuen T, Lu P, Bab I, Leu NA, Srinivasan S, Wagage S, Hunter CA, Nebert DW, Zaidi M, Avadhani NG.

Proc Natl Acad Sci U S A. 2013 Jul 2;110(27):11115-20. doi: 10.1073/pnas.1220919110. Epub 2013 Jun 17.

9.

Therapeutic potential of the inhibition of the retinoic acid hydroxylases CYP26A1 and CYP26B1 by xenobiotics.

Nelson CH, Buttrick BR, Isoherranen N.

Curr Top Med Chem. 2013;13(12):1402-28. Review.

10.

Insights on cytochrome p450 enzymes and inhibitors obtained through QSAR studies.

Sridhar J, Liu J, Foroozesh M, Stevens CL.

Molecules. 2012 Aug 3;17(8):9283-305. doi: 10.3390/molecules17089283. Review.

11.

Construction of a database for the evaluation and the clinical management of patients with breast cancer treated with antiestrogens and/or aromatase inhibitors.

Giusti F, Ottanelli S, Masi L, Amedei A, Brandi ML, Falchetti A.

Clin Cases Miner Bone Metab. 2011 Jan;8(1):37-50.

12.

First chemical feature-based pharmacophore modeling of potent retinoidal retinoic acid metabolism blocking agents (RAMBAs): identification of novel RAMBA scaffolds.

Purushottamachar P, Patel JB, Gediya LK, Clement OO, Njar VC.

Eur J Med Chem. 2012 Jan;47(1):412-23. doi: 10.1016/j.ejmech.2011.11.010. Epub 2011 Nov 17.

13.

EET signaling in cancer.

Panigrahy D, Greene ER, Pozzi A, Wang DW, Zeldin DC.

Cancer Metastasis Rev. 2011 Dec;30(3-4):525-40. doi: 10.1007/s10555-011-9315-y. Review.

14.
15.

Structural characterization of the complex between alpha-naphthoflavone and human cytochrome P450 1B1.

Wang A, Savas U, Stout CD, Johnson EF.

J Biol Chem. 2011 Feb 18;286(7):5736-43. doi: 10.1074/jbc.M110.204420. Epub 2010 Dec 8.

16.

Cytochrome P450-derived eicosanoids: the neglected pathway in cancer.

Panigrahy D, Kaipainen A, Greene ER, Huang S.

Cancer Metastasis Rev. 2010 Dec;29(4):723-35. doi: 10.1007/s10555-010-9264-x. Review.

17.

Targeting drug-metabolizing enzymes for effective chemoprevention and chemotherapy.

Swanson HI, Njar VC, Yu Z, Castro DJ, Gonzalez FJ, Williams DE, Huang Y, Kong AN, Doloff JC, Ma J, Waxman DJ, Scott EE.

Drug Metab Dispos. 2010 Apr;38(4):539-44. doi: 10.1124/dmd.109.031351.

18.

In silico studies of polyaromatic hydrocarbon inhibitors of cytochrome P450 enzymes 1A1, 1A2, 2A6, and 2B1.

Sridhar J, Jin P, Liu J, Foroozesh M, Stevens CL.

Chem Res Toxicol. 2010 Mar 15;23(3):600-7. doi: 10.1021/tx900348v.

19.

A suite of activity-based probes for human cytochrome P450 enzymes.

Wright AT, Song JD, Cravatt BF.

J Am Chem Soc. 2009 Aug 5;131(30):10692-700. doi: 10.1021/ja9037609.

20.

PGRMC1 (progesterone receptor membrane component 1): a targetable protein with multiple functions in steroid signaling, P450 activation and drug binding.

Rohe HJ, Ahmed IS, Twist KE, Craven RJ.

Pharmacol Ther. 2009 Jan;121(1):14-9. doi: 10.1016/j.pharmthera.2008.09.006. Epub 2008 Nov 1. Review.

Supplemental Content

Support Center